CLINICAL TRIALS PROFILE FOR FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN
✉ Email this page to a colleague
All Clinical Trials for FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00472966 ↗ | Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma | Completed | Galderma Laboratories, L.P. | Phase 4 | 2006-11-01 | To determine the effectiveness and safety of sequential therapy with of Tri-Luma® Cream and a series of Glycolic Acid peels in treatment of moderate to severe melasma. |
| NCT00669071 ↗ | Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma | Terminated | Galderma Laboratories, L.P. | Phase 4 | 2008-01-01 | This study is to evaluate the efficacy and safety of Tri-Luma® Cream (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) when used sequentially with a series of intense pulsed light (IPL) treatments in Subjects diagnosed with moderate to severe melasma during a 10 week treatment period. |
| NCT00975312 ↗ | Solar Lentigines Treatment With the Triple Combination Cream | Completed | Galderma Laboratories, L.P. | Phase 2 | 2008-08-01 | Background - Lentigines are usually the first sign of photoaging and may produce a significant impact on patients' quality of life. - There is no a treatment of choice for this condition. - Solar lentigines and melasma share similar physiopathologic characteristics. - The triple combination (TC) cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) has been effective and safe for the treatment of melasma and other hyperpigmented lesions. Hypothesis * The TC cream will be effective and safe for the treatment of solar lentigines on the back of the hands. Patients and methods - 22 patients with solar lentigines were selected and their right hand or left hand were selected at random to be treated with either TC cream or tretinoin 0.05% cream once daily for up 12 weeks. - Patients were instructed to apply both creams on the whole back of the hand and not only in the lentigines, and to use a broad-spectrum sunscreen (SPF 50+, UVA-PF 28) daily in both hands. - Clinical assessments of Target Lesion Pigmentation, Physician's Global Assessment of Improvement and a Subject's Self-Assessment questionnaire were collected for data analysis at weeks 4, 8, and 12 after starting the treatment and 3 month post-treatment. - Statistical methods: The ordinally scaled efficacy measures underwent rank transformation and were analyzed by analysis of variance to test the null hypothesis of no differences among treatments. We performed Mann-Whitney and Wilcoxon tests and the XLSTAT 2009 software was used. |
| NCT00975312 ↗ | Solar Lentigines Treatment With the Triple Combination Cream | Completed | Pontificia Universidad Catolica de Chile | Phase 2 | 2008-08-01 | Background - Lentigines are usually the first sign of photoaging and may produce a significant impact on patients' quality of life. - There is no a treatment of choice for this condition. - Solar lentigines and melasma share similar physiopathologic characteristics. - The triple combination (TC) cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) has been effective and safe for the treatment of melasma and other hyperpigmented lesions. Hypothesis * The TC cream will be effective and safe for the treatment of solar lentigines on the back of the hands. Patients and methods - 22 patients with solar lentigines were selected and their right hand or left hand were selected at random to be treated with either TC cream or tretinoin 0.05% cream once daily for up 12 weeks. - Patients were instructed to apply both creams on the whole back of the hand and not only in the lentigines, and to use a broad-spectrum sunscreen (SPF 50+, UVA-PF 28) daily in both hands. - Clinical assessments of Target Lesion Pigmentation, Physician's Global Assessment of Improvement and a Subject's Self-Assessment questionnaire were collected for data analysis at weeks 4, 8, and 12 after starting the treatment and 3 month post-treatment. - Statistical methods: The ordinally scaled efficacy measures underwent rank transformation and were analyzed by analysis of variance to test the null hypothesis of no differences among treatments. We performed Mann-Whitney and Wilcoxon tests and the XLSTAT 2009 software was used. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN
Condition Name
Clinical Trial Locations for FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN
Trials by Country
Clinical Trial Progress for FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN
Clinical Trial Phase
Clinical Trial Sponsors for FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN
Sponsor Name
